Iovance Biotherapeutics Inc (IOVA) concluded trading on Wednesday at a closing price of $7.26, with 7.01 million shares of worth about $50.9 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.91% during that period and on December 18, 2024 the price saw a loss of about -7.04%. Currently the company’s common shares owned by public are about 304.62M shares, out of which, 247.05M shares are available for trading.
Stock saw a price change of -15.38% in past 5 days and over the past one month there was a price change of -13.88%. Year-to-date (YTD), IOVA shares are showing a performance of -10.70% which decreased to -7.52% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.70 but also hit the highest price of $18.33 during that period. The average intraday trading volume for Iovance Biotherapeutics Inc shares is 5.99 million. The stock is currently trading -15.03% below its 20-day simple moving average (SMA20), while that difference is down -23.60% for SMA50 and it goes to -29.80% lower than SMA200.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) currently have 304.62M outstanding shares and institutions hold larger chunk of about 68.47% of that.
The stock has a current market capitalization of $2.21B and its 3Y-monthly beta is at 0.53. It has posted earnings per share of -$1.50 in the same period. It has Quick Ratio of 3.90 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IOVA, volatility over the week remained 6.16% while standing at 5.09% over the month.
Stock’s fiscal year EPS is expected to rise by 33.29% while it is estimated to increase by 34.44% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on October 24, 2024 offering a Buy rating for the stock and assigned a target price of $17 to it. Coverage by Piper Sandler stated Iovance Biotherapeutics Inc (IOVA) stock as a Neutral in their note to investors on July 29, 2024, suggesting a price target of $10 for the stock. On November 20, 2023, Goldman Initiated their recommendations, while on September 18, 2023, Barclays Reiterated their ratings for the stock with a price target of $18. Stock get an Overweight rating from Wells Fargo on May 30, 2023.
